AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion
Authors: Miller, KD Spooner, K Herpin, BR Rock-Kress, D Metcalf, JA Davey, RT Falloon, J Kovacs, JA Polis, RA Walker, RE Masur, H Lane, HC
Citation: Kd. Miller et al., Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion, CLIN IMMUNO, 99(1), 2001, pp. 30-42
Bioterrorism: A clear and present danger
Authors: Lane, HC La Montagne, J Fauci, AS
Citation: Hc. Lane et al., Bioterrorism: A clear and present danger, NAT MED, 7(12), 2001, pp. 1271-1273
Immunopathogenesis of human immunodeficiency virus: Implications for immune-based therapies
Authors: Sereti, I Lane, HC
Citation: I. Sereti et Hc. Lane, Immunopathogenesis of human immunodeficiency virus: Implications for immune-based therapies, CLIN INF D, 32(12), 2001, pp. 1738-1755
CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients
Authors: Sereti, I Herpin, B Metcalf, JA Stevens, R Baseler, MW Hallahan, CW Kovacs, JA Davey, RT Lane, HC
Citation: I. Sereti et al., CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients, AIDS, 15(14), 2001, pp. 1765-1775
Bioterrorism on the home front - A new challenge for American medicine
Authors: Lane, HC Fauci, AS
Citation: Hc. Lane et As. Fauci, Bioterrorism on the home front - A new challenge for American medicine, J AM MED A, 286(20), 2001, pp. 2595-2597
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of humanimmunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles
Authors: Imamichi, T Murphy, MA Imamichi, H Lane, HC
Citation: T. Imamichi et al., Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of humanimmunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles, J VIROLOGY, 75(8), 2001, pp. 3988-3992
Interleukin-2 in clinical trials: Other factors to be considered - Reply
Authors: Emery, S Lane, HC Neaton, JD
Citation: S. Emery et al., Interleukin-2 in clinical trials: Other factors to be considered - Reply, J INFEC DIS, 183(4), 2001, pp. 680-680
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viralquasi species present before initiation of therapy
Authors: Imamichi, H Crandall, KA Natarajan, V Jiang, MK Dewar, RL Berg, S Gaddam, A Bosche, M Metcalf, JA Davey, RT Lane, HC
Citation: H. Imamichi et al., Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viralquasi species present before initiation of therapy, J INFEC DIS, 183(1), 2001, pp. 36-50
Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy
Authors: Kovacs, JA Vogel, S Metcalf, JA Baseler, M Stevens, R Adelsberger, J Lempicki, R Hengel, RL Sereti, I Lambert, L Dewar, RL Davey, RT Walker, RE Falloon, J Polis, MA Masur, H Lane, HC
Citation: Ja. Kovacs et al., Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy, EUR J IMMUN, 31(5), 2001, pp. 1351-1360
Immunologic approaches to the therapy of patients with HIV infection
Authors: Lane, HC Seeley, S
Citation: Hc. Lane et S. Seeley, Immunologic approaches to the therapy of patients with HIV infection, INFEC DIS S, 2001, pp. 317-329
Interleukin 2 leads to dose-dependent expression of the alpha chain of theIL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation
Authors: Sereti, I Gea-Banacloche, J Kan, MY Hallahan, CW Lane, HC
Citation: I. Sereti et al., Interleukin 2 leads to dose-dependent expression of the alpha chain of theIL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation, CLIN IMMUNO, 97(3), 2000, pp. 266-276
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
Authors: Falloon, J Piscitelli, S Vogel, S Sadler, B Mitsuya, H Kavlick, MF Yoshimura, K Rogers, M LaFon, S Manion, DJ Lane, HC Masur, H
Citation: J. Falloon et al., Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity, CLIN INF D, 30(2), 2000, pp. 313-318
Longitudinal changes in CD4(+) T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients
Authors: Gea-Banacloche, JC Martino, L Mican, JM Hallahan, CW Baseler, M Stevens, R Lambert, L Polis, M Lane, HC Connors, M
Citation: Jc. Gea-banacloche et al., Longitudinal changes in CD4(+) T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients, AIDS RES H, 16(17), 2000, pp. 1877-1886
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
Authors: Ruxrungtham, K Suwanagool, S Tavel, JA Cheunyam, M Kroon, E Ubolyam, S Buranapraditkun, S Techasathit, W Li, YM Emery, S Davey, RT Fosdick, L Kunanusont, C Lane, HC Phanuphak, P
Citation: K. Ruxrungtham et al., A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand, AIDS, 14(16), 2000, pp. 2509-2513
Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
Authors: Orenstein, JM Bhat, N Yoder, C Fox, C Polis, MA Metcalf, JA Kovacs, JA Falloon, J Walker, RE Masur, H Lane, HC Davey, RT
Citation: Jm. Orenstein et al., Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression, AIDS, 14(12), 2000, pp. 1709-1715
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial
Authors: Davey, RT Murphy, RL Graziano, FM Boswell, SL Pavia, AT Cancio, M Nadler, JP Chaitt, DG Dewar, RL Sahner, DK Duliege, AM Capra, WB Leong, WP Giedlin, MA Lane, HC Kahn, JO
Citation: Rt. Davey et al., Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial, J AM MED A, 284(2), 2000, pp. 183-189
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4(+) and CD8(+) T cell turnover in HIV-infected patients
Authors: Lempicki, RA Kovacs, JA Baseler, MW Adelsberger, JW Dewar, RL Natarajan, V Bosche, MC Metcalf, JA Stevens, RA Lambert, LA Alvord, WG Polis, MA Davey, RT Dimitrov, DS Lane, HC
Citation: Ra. Lempicki et al., Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4(+) and CD8(+) T cell turnover in HIV-infected patients, P NAS US, 97(25), 2000, pp. 13778-13783
Relative replication fitness of a high-level 3 '-azido-3 '-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr -> Gly) at codon 69
Authors: Imamichi, T Berg, SC Imamichi, H Lopez, JC Metcalf, JA Falloon, J Lane, HC
Citation: T. Imamichi et al., Relative replication fitness of a high-level 3 '-azido-3 '-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr -> Gly) at codon 69, J VIROLOGY, 74(23), 2000, pp. 10958-10964
High-level resistance to 3 '-azido-3 '-deoxythimidine due to a deletion inthe reverse transcriptase gene of human immunodeficiency virus type 1
Authors: Imamichi, T Sinha, T Imamichi, H Zhang, YM Metcalf, JA Falloon, J Lane, HC
Citation: T. Imamichi et al., High-level resistance to 3 '-azido-3 '-deoxythimidine due to a deletion inthe reverse transcriptase gene of human immunodeficiency virus type 1, J VIROLOGY, 74(2), 2000, pp. 1023-1028
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
Authors: Kovacs, JA Imamichi, H Vogel, S Metcalf, JA Dewar, RL Baseler, M Stevens, R Adelsberger, J Lambert, L Davey, RT Walker, RE Falloon, J Polis, MA Masur, H Lane, HC
Citation: Ja. Kovacs et al., Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression, J INFEC DIS, 182(4), 2000, pp. 1063-1069
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
Authors: Emery, S Capra, WB Cooper, DA Mitsuyasu, RT Kovacs, JA Vig, P Smolskis, M Saravolatz, LD Lane, HC Fyfe, GA Curtin, PT
Citation: S. Emery et al., Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease, J INFEC DIS, 182(2), 2000, pp. 428-434
Evaluation of CD4(+) T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization
Authors: Fogelman, I Davey, V Ochs, HD Elashoff, M Feinberg, MB Mican, J Siegel, JP Sneller, M Lane, HC
Citation: I. Fogelman et al., Evaluation of CD4(+) T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization, J INFEC DIS, 182(2), 2000, pp. 435-441
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4(+) cell counts >=350/mm(3)
Authors: Losso, MH Belloso, WH Emery, S Benetucci, JA Cahn, PE Lasala, MC Lopardo, G Salomon, H Saracco, M Nelson, E Law, MG Davey, RT Allende, MC Lane, HC
Citation: Mh. Losso et al., A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4(+) cell counts >=350/mm(3), J INFEC DIS, 181(5), 2000, pp. 1614-1621
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
Authors: Walker, RE Bechtel, CM Natarajan, V Baseler, M Hege, KM Metcalf, JA Stevens, R Hazen, A Blaese, RM Chen, CC Leitman, SF Palensky, J Wittes, J Davey, RT Falloon, J Polis, MA Kovacs, JA Broad, DF Levine, BL Roberts, MR Masur, H Lane, HC
Citation: Re. Walker et al., Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection, BLOOD, 96(2), 2000, pp. 467-474
Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
Authors: Whitcup, SM Fortin, E Lindblad, AS Griffiths, P Metcalf, JA Robinson, MR Manischewitz, J Baird, B Perry, C Kidd, IM Vrabec, T Davey, RT Falloon, J Walker, RE Kovacs, JA Lane, HC Nussenblatt, RB Smith, J Masur, H Polis, MA
Citation: Sm. Whitcup et al., Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis, ARCH OPHTH, 118(5), 2000, pp. 704-704
Risultati: 1-25 | 26-36